Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Jun;1(2):72-80.
doi: 10.4021/jocmr2009.05.1237. Epub 2009 Jun 21.

5-Hydroxytryptamine Receptor Subtypes and their Modulators with Therapeutic Potentials

Anand B Pithadia  1 , Sunita M Jain
Affiliations

5-Hydroxytryptamine Receptor Subtypes and their Modulators with Therapeutic Potentials

Anand B Pithadia et al. J Clin Med Res. 2009 Jun.

Abstract

5-hydroxytryptamine (5-HT) has become one of the most investigated and complex biogenic amines. The main receptors and their subtypes, e.g., 5-HTI (5-HT1A, 5-HT1B, 5-HTID, 5-HTIE and 5-HT1F), 5-HT2 (5-HT2A, 5-HT2B and 5-HT2C), 5-HT3, 5-HT4, 5-HT5 (5-HT5A, 5-HT5B), 5-HT6 and 5-HT7 have been identified. Specific drugs which are capable of either selectively stimulating or inhibiting these receptor subtypes are being designed. This has generated therapeutic potentials of 5-HT receptor modulators in a variety of disease conditions. Conditions where 5-HT receptor modulators have established their use with distinct efficacy and advantages include migraine, anxiety, psychosis, obesity and cancer therapy-induced vomiting by cytotoxic drugs and radiation. Discovery of 5-HT, its biosynthesis, metabolism, physiological role and the potential of 5-HT receptor modulators in various nervous, cardiovascular and gastrointestinal tract disorders, bone growth and micturition have been discussed in this article.

Keywords: 5-hydroxytryptamine (5-HT) receptors; Modulators; Biogenic amines.

PubMed Disclaimer

Figures

Figure 1
Figure 1
5-HT causes hyperglycemia.
See this image and copyright information in PMC

References

    1. Rapport MM, Green AA, Page IH. Serum vasoconstrictor, serotonin; isolation and characterization. J Biol Chem. 1948;176(3):1243–1251. - PubMed
    1. Kleinrok Z. Biosynthesis and metabolism of 5-hydroxytryptamine in the central nervous system. Pol J Pharmacol Pharm. 1975;27(Suppl):3–12. - PubMed
    1. Gaddum JH, Picarelli ZP. Two kinds of tryptamine receptor. Br J Pharmacol Chemother. 1957;12(3):323–328. - PMC - PubMed
    1. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR. et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin) Pharmacol Rev. 1994;46(2):157–203. - PubMed
    1. Wong ML, Licinio J. Research and treatment approaches to depression. Nat Rev Neurosci. 2001;2(5):343–351. - PubMed

LinkOut - more resources